[{"Assets_0_Q2_USD":970483000.0,"CommonStockSharesOutstanding_0_Q2_shares":41107065.0,"EarningsPerShareBasic_2_Q2_USD":0.37,"EarningsPerShareBasic_1_Q2_USD":0.11,"EarningsPerShareDiluted_1_Q2_USD":0.11,"EarningsPerShareDiluted_2_Q2_USD":0.35,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":95673000.0,"NetIncomeLoss_1_Q2_USD":4616000.0,"NetIncomeLoss_2_Q2_USD":15101000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q2_shares":50078594.0,"WeightedAverageNumberOfDilutedSharesOutstanding_2_Q2_shares":49899291.0,"WeightedAverageNumberOfSharesOutstandingBasic_2_Q2_shares":40871540.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q2_shares":41013764.0,"Ticker":"EBS","CIK":"1367644","name":"EMERGENT BIOSOLUTIONS INC.","OfficialName":"Emergent Biosolutions Inc. Common Stock","form":"10-Q","period":"20170630","fy":"2017.0","fp":"Q2","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"2077670312.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NYSE","SP500":"nan","filed":"20170804"}]